Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Brzozow – page 3

41 clinical trials in Brzozow, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Brzozow at a glance
41
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

41 trials in Brzozow

Open in trial search

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Renal cell carcinoma+1

Not recruiting

Study of Axitinib and Immune Checkpoint Inhibitors for Patients with Untreated Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

B-cell small lymphocytic lymphoma

Not recruiting

Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Myelofibrosis

Not recruiting

Study on Extended Access to Momelotinib for Patients with Myelofibrosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Mantle cell lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Brzozow

What the registry says about research in the country

01 Hematologic Malignancies

Groundbreaking clinical trials focusing on multiple myeloma, leukemia, and lymphoma treatments. Studies evaluate novel combination therapies and targeted approaches for both newly diagnosed and relapsed/refractory patients.

  • Multiple Myeloma Treatment Innovations
  • Chronic Lymphocytic Leukemia Research
  • Mantle Cell Lymphoma Therapies

Research includes evaluation of monoclonal antibodies, targeted therapies, and immunotherapy combinations.

02 Gastrointestinal Oncology

Studies examining advanced treatments for gastric cancer and colorectal cancer, with particular focus on targeted therapies for specific genetic mutations and biomarker-driven approaches.

  • BRAF-Mutant Colorectal Cancer
  • Gastroesophageal Junction Cancer
  • Novel Combination Therapies

Trials incorporate innovative treatment combinations including immunotherapy and targeted agents.

03 Advanced Therapeutics

Cutting-edge research evaluating personalized treatment strategies across various cancer types, including studies of novel drug combinations and targeted approaches for rare conditions.

  • Myeloproliferative Disorders
  • Breast Cancer Innovations
  • Renal Cell Carcinoma Treatment

Focus on precision medicine approaches and biomarker-driven treatment selection.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.